Share-based Payment Arrangement, Expense in USD of Cytosorbents Corp from 2011 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cytosorbents Corp quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2011 to Q1 2025.
  • Cytosorbents Corp Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $818,426.000, a 14.7% decline year-over-year.
  • Cytosorbents Corp Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $3,658,961.000, a 15.5% decline year-over-year.
  • Cytosorbents Corp annual Share-based Payment Arrangement, Expense for 2024 was $3,800,000.000, a 9.52% decline from 2023.
  • Cytosorbents Corp annual Share-based Payment Arrangement, Expense for 2023 was $4,200,000.000, a 22.7% increase from 2022.
  • Cytosorbents Corp annual Share-based Payment Arrangement, Expense for 2022 was $3,424,000.000, a 14.8% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cytosorbents Corp Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $3,658,961 $818,426 -$141,039 -14.7% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025
Q4 2024 $3,800,000 $1,229,535 -$484,465 -28.3% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 $4,284,465 $782,000 -$304,000 -28% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024
Q2 2024 $4,588,465 $829,000 +$259,000 +45.4% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2024
Q1 2024 $4,329,465 $959,465 +$129,465 +15.6% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025
Q4 2023 $4,200,000 $1,714,000 +$843,000 +96.8% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 $3,357,000 $1,086,000 +$81,000 +8.1% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 $3,276,000 $570,000 -$191,000 -25.1% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 $3,467,000 $830,000 +$43,000 +5.5% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q4 2022 $3,424,000 $871,000 +$965,000 01 Oct 2022 31 Dec 2022 10-K 15 Mar 2024
Q3 2022 $2,459,000 $1,005,000 +$6,000 +0.6% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 $2,453,000 $761,000 -$797,000 -51.2% 01 Apr 2022 30 Jun 2022 10-Q 01 Aug 2023
Q1 2022 $3,250,000 $787,000 -$771,000 -49.5% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023
Q4 2021 $4,021,000 -$94,000 -$745,000 -1.1% 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2024
Q3 2021 $4,766,000 $999,000 -$89,000 -8.2% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 $4,855,000 $1,558,000 +$512,000 +48.9% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2021
Q1 2021 $4,343,000 $1,558,000 +$829,000 +1.1% 01 Jan 2021 31 Mar 2021 10-Q 02 Aug 2022
Q4 2020 $3,514,000 $651,000 +$160,000 +32.6% 01 Oct 2020 31 Dec 2020 10-K 09 Mar 2023
Q3 2020 $3,354,000 $1,088,000 +$286,000 +35.7% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021
Q2 2020 $3,068,000 $1,046,000 +$901,000 +6.2% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021
Q1 2020 $2,167,000 $729,000 +$501,000 +2.2% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021
Q4 2019 $1,666,000 $491,000 -$1,082,000 -68.8% 01 Oct 2019 31 Dec 2019 10-K 10 Mar 2022
Q3 2019 $2,748,000 $802,000 +$528,000 +1.9% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020
Q2 2019 $2,220,000 $145,000 -$1,921,000 -93% 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020
Q1 2019 $4,141,000 $228,000 -$296,000 -56.5% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020
Q4 2018 $4,437,000 $1,573,000 +$110,000 +7.5% 01 Oct 2018 31 Dec 2018 10-K 09 Mar 2021
Q3 2018 $4,327,000 $274,000 -$686,000 -71.5% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019
Q2 2018 $5,013,000 $2,066,000 +$1,267,000 +1.6% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019
Q1 2018 $3,746,000 $524,000 +$432,000 +4.7% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019
Q4 2017 $3,314,000 $1,463,000 -$695,000 -32.2% 01 Oct 2017 31 Dec 2017 10-K 05 Mar 2020
Q3 2017 $4,009,000 $960,000 +$836,000 +6.7% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2017
Q2 2017 $3,173,000 $799,000 +$431,000 +1.2% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2017
Q1 2017 $2,742,000 $92,000 -$15,000 -14% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018
Q4 2016 $2,757,000 $2,158,000 +$2,073,000 +24.4% 01 Oct 2016 31 Dec 2016 10-K 07 Mar 2019
Q3 2016 $684,000 $124,000 -$26,000 -17.3% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 $710,000 $368,000 +$285,000 +3.4% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017
Q1 2016 $425,000 $107,000 +$43,000 +67.2% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017
Q4 2015 $382,000 $85,000 01 Oct 2015 31 Dec 2015 10-K 08 Mar 2018
Q3 2015 $150,000 01 Jul 2015 30 Sep 2015 10-Q 13 Nov 2015
Q2 2015 $83,000 01 Apr 2015 30 Jun 2015 10-Q 13 Aug 2015
Q1 2015 $64,000 +$7,000 +12.3% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016
Q1 2014 $57,000 -$168,900 -74.8% 01 Jan 2014 31 Mar 2014 10-Q 14 May 2014
Q1 2013 $225,900 01 Jan 2013 31 Mar 2013 10-Q 15 May 2013

Cytosorbents Corp Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $3,800,000 -$400,000 -9.5% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 $4,200,000 +$776,000 +22.7% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 $3,424,000 -$597,000 -14.8% 01 Jan 2022 31 Dec 2022 10-K 15 Mar 2024
2021 $4,021,000 +$507,000 +14.4% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2024
2020 $3,514,000 +$1,848,000 +1.1% 01 Jan 2020 31 Dec 2020 10-K 09 Mar 2023
2019 $1,666,000 -$2,771,000 -62.5% 01 Jan 2019 31 Dec 2019 10-K 10 Mar 2022
2018 $4,437,000 +$1,123,000 +33.9% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2021
2017 $3,314,000 +$557,000 +20.2% 01 Jan 2017 31 Dec 2017 10-K 05 Mar 2020
2016 $2,757,000 +$2,375,000 +6.2% 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2019
2015 $382,000 -$314,000 -45.1% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018
2014 $696,000 +$239,100 +52.3% 01 Jan 2014 31 Dec 2014 10-K 03 Mar 2017
2013 $456,900 +$393,800 +6.2% 01 Jan 2013 31 Dec 2013 10-K 31 Mar 2015
2012 $63,100 -$802,400 -92.7% 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2014
2011 $865,500 01 Jan 2011 31 Dec 2011 10-K 03 Apr 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.